STOCK TITAN

Aptevo Therapeutics raises about $3M in warrant deal

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. (APVO) closed a warrant inducement transaction on November 12, 2026. Holders exercised existing warrants for cash to purchase 2,777,778 common shares at a reduced price of $1.08 per share, generating approximately $3.0 million in gross proceeds before fees and expenses. Aptevo issued unregistered warrants to purchase up to 13,888,890 common shares at $1.08 per share, representing 500% of the shares issued in the exercise.

The new warrants become exercisable on or after required stockholder approval and expire on the fifth anniversary of that approval. Full cash exercise would generate approximately $15.0 million in additional gross proceeds. Aptevo intends to use net proceeds for working capital and general corporate purposes, and agreed to file a registration statement covering resale of shares issuable under the new warrants. Holders may not exercise above an elected 4.99% or 9.99% beneficial-ownership limit. For one year after closing, the ratio of Aptevo’s next reverse stock split will not exceed 1-for-10.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Existing warrant shares exercised 2,777,778 shares Cash exercise under the warrant inducement transaction
Existing warrant exercise price $1.08 per share Reduced price paid in the cash exercise
Gross proceeds received Approximately $3.0 million Before placement agent fees and other expenses
Inducement warrant shares Up to 13,888,890 shares Unregistered warrants issued in the transaction
Inducement warrant exercise price $1.08 per share Applies to exercise of the new warrants
Inducement warrants relative to shares exercised 500% Percentage of the number of existing warrant shares issued in the exercise
Potential additional gross proceeds Approximately $15.0 million If the inducement warrants are exercised in full for cash
Beneficial-ownership exercise limit 4.99% or 9.99% Holder may elect the limit applicable to its warrant exercises
Inducement Warrants financial
"new unregistered common stock purchase warrants"
gross proceeds financial
"aggregate gross proceeds of approximately $3.0 million"
The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.
fundamental transaction technical
"upon a fundamental transaction"
variable rate transactions financial
"limitation on subsequent equity sales and variable rate transactions"
Rule 506 regulatory
"Rule 506 promulgated thereunder"
A Securities and Exchange Commission rule that lets companies sell securities without registering them with the SEC when they meet certain conditions, commonly used for private placements. It allows issuers to raise unlimited capital from accredited investors and, in some versions, a small number of knowledgeable non‑accredited investors; one version also permits public advertising if the seller takes steps to verify investor credentials. For investors, it signals a private offering with lighter disclosure and different protections than a public stock sale, similar to buying into a private club rather than a publicly traded marketplace.
beneficially own financial
"would beneficially own in excess of 4.99% or 9.99%"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much cash did APVO receive from the warrant exercise?

Aptevo received approximately $3.0 million in gross proceeds before placement agent fees and other expenses.

How many shares can APVO's new inducement warrants purchase?

The new warrants cover up to 13,888,890 common shares at an exercise price of $1.08 per share. They become exercisable on or after required stockholder approval; full cash exercise would generate approximately $15.0 million in additional gross proceeds.

Are APVO's new warrants and the underlying shares registered?

The warrants and shares issuable upon exercise were offered in a private placement and have not been registered. Aptevo agreed to file a registration statement covering resale of the underlying shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001671584false00016715842026-11-112026-11-11

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 11, 2026

 

 

APTEVO THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37746

81-1567056

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2401 4th Avenue

Suite 1050

 

Seattle, Washington

 

98121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (206) 838-0500

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

APVO

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 


Item 1.01 Entry into a Material Definitive Agreement.

On November 11, 2026, Aptevo Therapeutics Inc. (the “Company”) entered into Warrant Inducement and Reload Letters (the “Inducement Letters”) with certain holders (the “Holders”) of the Company’s inducement common stock purchase warrants and PIPE common stock purchase warrants, each issued on August 13, 2026 (the “Existing Warrants”), pursuant to which the Holders agreed to exercise in full for cash the Existing Warrants to purchase up to an aggregate of 2,777,778 shares of common stock (“Common Stock”) of the Company (the “Existing Warrant Shares”) at a reduced exercise price of $1.08 per share (the “Warrant Exercise”).

In consideration of the Holders’ agreement to exercise the Existing Warrants in accordance with the Inducement Letters, the Company issued new unregistered common stock purchase warrants (the “Inducement Warrants”) to purchase up to an aggregate of 13,888,890 shares of Common Stock (the “Inducement Warrant Shares”), representing 500% of the number of Existing Warrant Shares issued pursuant to the Warrant Exercise, at an exercise price of $1.08 per share (the “Warrant Reload” and, together with the Warrant Exercise, the “Transaction”). The Inducement Warrants will be exercisable on or after the date on which the Company obtains the required stockholder approval and will expire on the five-year anniversary of the date of such stockholder approval.

The Company received aggregate gross proceeds of approximately $3.0 million from the Warrant Exercise, before deducting placement agent fees and other offering expenses payable by the Company. If the Inducement Warrants are exercised in full for cash, the Company would receive additional gross proceeds of approximately $15.0 million. The Company intends to use the net proceeds from the Transaction for working capital and general corporate purposes. The closing of the Transaction occurred on November 12, 2026.

The exercise price and the number of shares of Common Stock issuable upon exercise of each Inducement Warrant are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock. In addition, in certain circumstances, upon a fundamental transaction, a holder of the Inducement Warrants will be entitled to receive, upon exercise of such warrants, the kind and amount of securities, cash or other property that such holder would have received had they exercised the warrants immediately prior to the fundamental transaction.

A Holder may not exercise any portion of its Inducement Warrants to the extent that the Holder, together with its affiliates and any other persons acting as a group together with the holder or any of its affiliates, would beneficially own in excess of 4.99% or 9.99%, as elected by the Holder, of the number of shares of Common Stock outstanding immediately after giving effect to the exercise.

 

The Inducement Letters contain customary representations, warranties and agreements of the Company, including, but not limited to, the obligation to register the Inducement Warrant Shares under the Securities Act of 1933, as amended (the “Securities Act”), and certain limitation on subsequent equity sales and variable rate transactions of the Company. In addition, the Company has agreed that, for a period of one year following the closing date of the Transaction, the ratio of its next reverse stock split will not exceed 1-for-10.

The foregoing descriptions of the Inducement Letters and the Inducement Warrants do not purport to be complete and are qualified in their entirety by reference to the full text of the Inducement Letters and the Inducement Warrants, which are filed as Exhibits 10.1 and 4.1, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities.

 

The disclosure required by this Item and included in Item 1.01 of this Current Report is incorporated herein by reference. The Inducement Warrants and the Inducement Warrant Shares described above were offered in a private placement transaction pursuant to Section 4(a)(2) of the Securities Act and Rule 506 promulgated thereunder, as applicable, and have not been registered under the Securities Act and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from such registration requirements.

 

Item 8.01 Other Events.

 

The Company issued a press release announcing the Transaction on November 11, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

 

 

 


Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

 

Description

4.1

 

Form of Inducement Warrant

10.1

 

Form of Inducement Letter, by and between the Company and each Holder

99.1

 

Press release, dated November 11, 2026

99.2

 

Press release, dated November 12, 2026

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

APTEVO THERAPEUTICS INC.

 

 

 

 

Date:

November 12, 2026

By:

/s/ Daphne Taylor

 

 

 

Daphne Taylor
Senior Vice President and Chief Financial Officer

 

 

 

 


Exhibit 99.1

img237228349_0.gif

Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds

SEATTLE, WASHINGTON - November 11, 2026 - Aptevo Therapeutics Inc. (NASDAQ:APVO) (“Aptevo” or the “Company”), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced that the Company closed its previously announced warrant inducement transaction with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have exercised in full for cash their Existing Warrants to purchase up to an aggregate of 2,777,778 shares of common stock of the Company ("common stock") at a reduced exercise price of $1.08 per share.

In consideration for such cash exercises, the Company will issue new unregistered common stock purchase warrants (the “Inducement Warrants”) to purchase up to an aggregate of 13,888,890 shares of common stock at an exercise price of $1.08 per share. The Inducement Warrants will be exercisable on or after the date on which the Company obtains the required stockholder approval and will expire five years after their initial exercise date. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-298483).

The aggregate gross proceeds from the transaction described herein are expected to total approximately $3.0 million, before deducting placement agent fees and expenses.

Roth Capital Partners is acting as the Company's financial advisor in connection with this transaction.

The transaction is expected to close on or about November 12, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the transaction for working capital purposes.

The Inducement Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933 (the “Securities Act”). The Inducement Warrants, along with the common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of common stock issuable upon exercise of the New Warrants.


This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or exemption under the securities laws of any such state or jurisdiction.

About Aptevo

Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for the treatment of cancer. The Company's lead clinical candidate, mipletamig, is currently being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax and azacitidine. Mipletamig has received orphan drug designation for AML under the Orphan Drug Act.

 

In the solid tumor space, Aptevo's lead assets are focused on well-established targets to progress novel immunomodulatory platform backbones that are conditionally active only in the tumor.

 

This work includes advancing APVO451, a targeted trispecific immunotherapy candidate for solid tumors, and a strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology programs. The first radiopharmaceutical program is expected to target nectin-4, a tumor-associated antigen expressed in multiple solid tumor types. Both preclinical molecules are expected to advance into investigational new drug (IND)-enabling studies in 2027.

 

The Company's eight pipeline candidates are created using its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms, which are designed to generate differentiated multispecific therapeutics. For more information, please visit www.aptevotherapeutics.com.

 

Cautionary Note Regarding Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, statements regarding the closing of the transaction described herein, the satisfaction of the closing conditions of the transaction, the use of net proceeds from the transaction, and any other statements containing the words “may,” “continue to,” “believes,” “knows,” “expects,” “optimism,” “potential,” “designed,” “promising,” "plans,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.

 


There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; the inability to obtain, maintain or enforce intellectual property protection; further assessment of preliminary or interim data or different results from later studies; adverse events and unanticipated problems; adverse developments in clinical or preclinical development, including unexpected safety issues; constraints in radioisotope availability, manufacturing or supply; and changes in regulatory, social, macroeconomic and political conditions. Additional risks and factors that may affect results are set forth in Aptevo's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, its subsequent report on Form 10-Q and current reports on Form 8-K. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events or circumstances.

Contact Information

Miriam Weber Miller

VP, Investor Relations & Corporate Communications

Aptevo Therapeutics

Email: IR@apvo.com or Millerm@apvo.com

Phone: 206-859-6628

 


 

Exhibit 99.2

 

img238151870_0.gif

Aptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross Proceeds

SEATTLE, WASHINGTON - November 12, 2026 - Aptevo Therapeutics Inc. (NASDAQ:APVO) (“Aptevo” or the “Company”), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced that the Company has entered into warrant inducement letter agreements with certain holders of its existing common warrants (the “Existing Warrants”), pursuant to which such holders have agreed to exercise in full for cash their Existing Warrants to purchase up to an aggregate of 2,777,778 shares of common stock of the Company (“common stock”) at a reduced exercise price of $1.08 per share. In consideration for such cash exercises, the Company will issue new unregistered common stock purchase warrants (the “Inducement Warrants”) to purchase up to an aggregate of 13,888,890 shares of common stock at an exercise price of $1.08 per share. The Inducement Warrants will be exercisable on or after the date on which the Company obtains the required stockholder approval and will expire five years after their initial exercise date. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-298483).

The aggregate gross proceeds from the transaction described herein were approximately $3.0 million, before deducting placement agent fees and expenses.

Roth Capital Partners acted as the Company's financial advisor in connection with this transaction.

The Inducement Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933 (the “Securities Act”). The Inducement Warrants, along with the common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of common stock issuable upon exercise of the Inducement Warrants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or exemption under the securities laws of any such state or jurisdiction.

 


 

About Aptevo

Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for the treatment of cancer. The Company's lead clinical candidate, mipletamig, is currently being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax and azacitidine. Mipletamig has received orphan drug designation for AML under the Orphan Drug Act.

 

In the solid tumor space, Aptevo's lead assets are focused on well-established targets to progress novel immunomodulatory platform backbones that are conditionally active only in the tumor.

 

This work includes advancing APVO451, a targeted trispecific immunotherapy candidate for solid tumors, and a strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology programs. The first radiopharmaceutical program is expected to target nectin-4, a tumor-associated antigen expressed in multiple solid tumor types. Both preclinical molecules are expected to advance into investigational new drug (IND)-enabling studies in 2027.

 

The Company's eight pipeline candidates are created using its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms, which are designed to generate differentiated multispecific therapeutics. For more information, please visit www.aptevotherapeutics.com.

 

Cautionary Note Regarding Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, the use of net proceeds from the transaction, and any other statements containing the words “may,” “continue to,” “believes,” “knows,” “expects,” “optimism,” “potential,” “designed,” “promising,” "plans,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.

There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; the inability to obtain, maintain or enforce intellectual property protection; further assessment of preliminary or interim data or different results from later studies; adverse events and unanticipated problems; adverse developments in clinical or preclinical development, including unexpected safety issues; constraints in radioisotope availability, manufacturing or supply; and changes in regulatory, social, macroeconomic and political conditions. Additional risks and factors that may affect results are set forth in Aptevo's

 


 

filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, its subsequent report on Form 10-Q and current reports on Form 8-K. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events or circumstances.

Contact Information

Miriam Weber Miller

VP, Investor Relations & Corporate Communications

Aptevo Therapeutics

Email: IR@apvo.com or Millerm@apvo.com

Phone: 206-859-6628

 

 


Filing Exhibits & Attachments

5 documents

Keep reading